PTH and postmenopausal osteoporosis: As a consequence, the rate and extent of bone loss after SCI is substantially greater than those of other pathological conditions predisposing to osteoporosis, such as prolonged bedrest, microgravity during spaceflight, or postmenopausal osteoporosis.[14] Another major concern is that teriparatide and abaloparatide (PTH‐related protein analog) treatment is limited to a 2‐year period in patients because of the increased potential risk of developing osteosarcoma with a longer duration of therapy.[82, 83]